Understanding Male Breast Cancer: Salah Azaïz Cancer Institute Experience

Status Active, not recruiting

Clinical Trial Summary

The goal of this study is to evaluate the Salah Azaïz Cancer Institute male breast cancer patients population over a period of 14 years.

Goal of the retrospective part: to gather clinicopathologic data and follow-up outcomes of male breast cancer patients diagnosed and/or treated at Salah Azaïz Cancer Institute from 2004 to 2013.

Goal of the prospective part: to create a registry of male patients with breast cancer for a period of 48 months (from 2014 to 2017).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03240510
Study type	Observational
Source	Salah Azaïz Cancer Institute
Contact
Status	Active, not recruiting
Phase	N/A
Start date	January 1, 2014
Completion date	January 1, 2018

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02480933` - Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens	N/A
Terminated	`NCT01705340` - Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery	Phase 1
Terminated	`NCT01222377` - Endoscopic Breast Surgery in Treating Patients With Breast Cancer	N/A
Completed	`NCT00425672` - ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment	Phase 1/Phase 2
Completed	`NCT00244881` - A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)	Phase 2
Completed	`NCT00096434` - Sorafenib in Treating Patients With Metastatic Breast Cancer	Phase 2
Terminated	`NCT01217411` - RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer	Phase 1
Completed	`NCT01037790` - Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer	Phase 2
Active, not recruiting	`NCT00791037` - Vaccine Therapy in Treating Patients With Stage IV Breast Cancer	Phase 1/Phase 2
Completed	`NCT00559507` - Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery	Phase 2
Completed	`NCT00119262` - Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer	Phase 2
Completed	`NCT00098605` - Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases	Phase 2
Terminated	`NCT00095888` - 3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer	Phase 2
Completed	`NCT00068588` - GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer	Phase 2
Terminated	`NCT00071942` - Vaccine Therapy in Treating Patients With Metastatic Breast Cancer	Phase 1
Recruiting	`NCT05501704` - ETHAN - ET for Male BC	Phase 2
Completed	`NCT01869764` - Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer	Phase 2
Completed	`NCT02046421` - Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer	Phase 1
Completed	`NCT01720602` - Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy	N/A
Terminated	`NCT01931709` - FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer	N/A